Why are hot flashes and other menopause symptoms often more sudden and severe after surgical menopause (both ovaries removed) than after natural menopause, and does hormone therapy control them as effectively?

Yes, symptoms typically arrive more suddenly and more intensely after surgical menopause than after natural menopause, and the reason is mechanical, not just perceived.

Natural menopause follows years of gradual perimenopausal decline that gives the body time to adjust, while removing both ovaries drops estrogen and progesterone abruptly, sometimes within days. Observational research comparing women who had risk-reducing ovary removal to women with natural menopause found roughly double the climacteric symptom burden on a standardized scale, with more severe hot flashes, sleep disruption, mood symptoms and sexual dysfunction, though overall quality of life was not reported as worse. Hormone therapy is the standard first-line treatment for these symptoms in surgical menopause just as in natural menopause, and current guidance calls for starting it soon after surgery rather than waiting, especially under age 45. No trial has directly compared how well hormone therapy works between surgically and naturally menopausal women, so effectiveness estimates rely on general hormone therapy evidence and observational data rather than a head-to-head study. For women who had the surgery young, current international guidance increasingly frames hormone therapy less as symptom relief alone and more as foundational protection against the long-term cardiovascular, bone and cognitive risks of extra years of estrogen deficiency, typically continued until around the average age of natural menopause, near 51.

What to know about this answer

Guideline bodies treat surgical menopause as an urgent case for the same hormone therapy already recommended for early natural menopause, on the reasoning that the underlying estrogen deficiency and its risks are the same or worse. Some clinicians caution that treating surgical menopause as simply an earlier version of natural menopause oversimplifies it: the abruptness of the drop, the younger average age, and complicating factors like a BRCA mutation or a cancer diagnosis behind the surgery can change what dose, route and duration of hormone therapy actually make sense, and no trial has directly compared hormone therapy's effectiveness between surgically and naturally menopausal women.

What the research shows, and which source each finding rests on

A 2026 joint position paper from FIGO and the International Menopause Society calls for reframing hormone therapy in premature ovarian insufficiency and early menopause, including surgical menopause, as foundational care to prevent long-term cardiovascular, skeletal, cognitive and psychological disability, not only as symptom relief, and argues that timely initiation, adequate dosing and long-term continuation should be standard rather than fragmented or delayed.

?[1]

A study comparing 48 women who had risk-reducing bilateral salpingo-oophorectomy to 60 women who had natural menopause found significantly more severe psychological, vasomotor and somatic climacteric symptoms after surgical menopause on the Greene Climacteric Scale (total score 17.36 versus 8.65, p less than 0.001) and more sexual dysfunction, although the surgery did not appear to reduce overall perceived quality of life.

?[2]

A review of the Mayo Clinic Cohort Study of Oophorectomy and Aging found that bilateral oophorectomy performed before natural menopause is associated with increased long-term risk of premature death, cardiovascular disease, cognitive impairment or dementia, parkinsonism, osteoporosis and decline in psychological and sexual wellbeing, and that estrogen treatment may prevent some but not all of these outcomes.

?[3]

In women with BRCA1 or BRCA2 mutations who undergo risk-reducing bilateral salpingo-oophorectomy at ages 35 to 45, review evidence supports hormone therapy continued until around the average age of natural menopause to help offset the cardiovascular, bone and cognitive risks of premature surgical menopause.

?[4]

A clinical review on hormone therapy after hysterectomy concludes that when bilateral oophorectomy is performed before natural menopause, the onset of vasomotor symptoms, genital tract atrophy and decline in sexual function is more rapid and more severe than with natural menopause, which accelerates the need for a hormone therapy decision.

?[5]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

surgical menopause should be treated with urgency, using the same hormone therapy framework as early natural menopause

FIGO and the International Menopause Society in their joint 2026 position paper

The FIGO and IMS position paper calls for reframing hormone therapy in premature ovarian insufficiency and early menopause, including surgical menopause, as foundational care to prevent long-term cardiovascular, skeletal and cognitive disability, not merely as symptom relief, and states that current practice is too often fragmented and delayed.

?[1]

surgical menopause needs individualized dosing and counseling, not a copy of the standard natural-menopause protocol

clinicians writing surgical-menopause management guidance and reviewers of hereditary-cancer risk-reducing surgery

Because the estrogen drop is abrupt rather than gradual and symptoms are often more severe under age 45, clinical toolkits call for closer, individualized counseling, and reviewers of BRCA-related risk-reducing surgery note the added complexity of weighing hormone therapy against any residual cancer risk, which a standard natural-menopause protocol does not address.

?[6]?[4]

What would settle it: A randomized or prospective trial that enrolls both surgically and naturally menopausal women of similar age onto the same hormone therapy regimen and compares symptom relief, required dosing and long-term outcomes head to head. No such trial currently exists; current guidance extrapolates from general hormone therapy evidence and separate observational cohorts.

What is really going on here

Was I told hormone therapy is only about hot flashes, or did anyone mention it may also matter for my long-term heart, bone and brain health because I lost estrogen so early?
Is my dose or route of hormone therapy being adjusted for the fact that I lost ovarian function suddenly and at a younger age, or am I on a standard postmenopausal starting dose?
If I cannot take estrogen because of a hormone-sensitive cancer risk, what non-hormonal options actually exist for these symptoms and for long-term bone and heart protection?

Questions for your doctor

Now that I have had both ovaries removed, should hormone therapy start right away, and is there a downside to waiting?
How does having surgical menopause instead of natural menopause change the dose, route or duration of hormone therapy that makes sense for me?
If this surgery was done because of a cancer risk, like a BRCA mutation, or alongside a cancer diagnosis, does that change whether hormone therapy is safe for me?
Beyond hot flashes and sleep, what should I be doing to protect my bones, heart and brain given how early my estrogen dropped?

Questions with no answer yet

Does hormone therapy relieve hot flashes and night sweats as effectively in surgical menopause as it does in natural menopause, or does the abruptness of the estrogen drop change how well or how much therapy is needed?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: Hormone therapy is established as the most effective treatment for vasomotor symptoms in postmenopausal women broadly, and women who underwent risk-reducing bilateral salpingo-oophorectomy report a climacteric symptom burden more than double that of women with natural menopause on a standardized scale. But no randomized trial has enrolled surgically and naturally menopausal women side by side on the same hormone therapy regimen to directly compare how well it controls their symptoms.

What would test it: A randomized or prospective trial that recruits both surgically and naturally menopausal women of similar age onto the same hormone therapy regimen and compares symptom trajectories, required doses and time to relief head to head.

Do women who start hormone therapy soon after surgical menopause need different doses or routes of estrogen than women starting it for natural menopause?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: Clinical guidance on surgical menopause notes it often needs closer, individualized dosing and counseling than natural menopause, especially under age 45. Separately, research in rats found that the timing of estradiol replacement relative to ovariectomy changed how effectively it modulated a marker of brain cholinergic activity, hinting that timing may matter biologically, but this is animal data and has not been tested in women. No human trial has directly compared hormone therapy doses or routes between surgically and naturally menopausal women.

What would test it: A dose-finding or comparative-effectiveness trial in surgically menopausal women testing standard-dose versus higher-dose or different-route hormone therapy against symptom relief and biomarker endpoints, ideally alongside a matched natural-menopause comparison group.

For women who had surgical menopause at a young age because of a BRCA mutation or another hereditary cancer risk, how should the long-term case for hormone therapy be weighed against any residual cancer risk?

Studied and reassuring so far

What is known: Reviews of BRCA1/2 carriers after risk-reducing bilateral salpingo-oophorectomy report that hormone therapy used until around the average age of natural menopause has not been shown to negate the cancer-risk-reduction benefit of the surgery in carriers without a personal breast cancer history, and support its use to offset the cardiovascular, bone and cognitive risks of premature surgical menopause. The picture is reassuring but still evolving, especially for women who also have a personal cancer history, where hormone therapy decisions require individualized oncology input.

What would test it: Longer-term prospective registry data tracking cancer outcomes and long-term health outcomes side by side in BRCA carriers who do versus do not use hormone therapy after risk-reducing surgery, stratified by personal cancer history.

Sources

1.Benedetto C et al. (FIGO and IMS joint position paper), Climacteric 2026Not rated
2.Benshushan A et al., Climacteric 2009Not rated
3.Shuster LT et al. (Mayo Clinic Cohort Study of Oophorectomy and Aging), Menopause Int 2008Not rated
4.Nitschke AS et al., Cancers (Basel) 2023Not rated
5.Haney AF, Wild RA, Menopause 2007Not rated
6.Garg A, Robinson L, Post Reprod Health 2021Not rated

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping